checkAd

     113  0 Kommentare ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA - Seite 3

    ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

    ZYNLONTA is a registered trademark of ADC Therapeutics SA.

    Lesen Sie auch


    Business Wire (engl.)
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von Business Wire (engl.)
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    ADC Therapeutics Receives Orphan Drug Designation in Europe for ZYNLONTA - Seite 3 ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that the European Commission has …